G protein-coupled receptor associated sorting protein 2Genealiases: DFNX7 · GASP2
Q-omics provides the consensus-scored GPRASP2 profile across patient tissues and cancer cell-line models. GPRASP2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPRASP2 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, GPRASP2 RNA expression shows 21,743 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where GPRASP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPRASP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPRASP2 survival associations across molecular data types. GPRASP2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPRASP2 RNA expression–survival associations across cancer types. High GPRASP2 expression shows unfavorable associations in BLCA and COAD, but favorable associations in KIRC, ACC, PAAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPRASP2 RNA expression.
This table summarizes GPRASP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPRASP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPRASP2 shows lower tumor expression in BLCA, KICH, THCA, KIRC, UCEC and BRCA. The BLCA box plot shows higher GPRASP2 RNA expression in normal versus tumor tissue (log2 FC = −1.947, t-test p < 0.001).
This table shows molecular features associated with GPRASP2 in patient tissues and cancer cell lines. In patient samples, GPRASP2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPRASP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LUNG_NSCLC_LUAD.
